These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 11340633

  • 1. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study.
    Djavan B, Mazal P, Zlotta A, Wammack R, Ravery V, Remzi M, Susani M, Borkowski A, Hruby S, Boccon-Gibod L, Schulman CC, Marberger M.
    Prostate; 2001 May 01; 47(2):111-7. PubMed ID: 11340633
    [Abstract] [Full Text] [Related]

  • 2. Prostate biopsy: who, how and when. An update.
    Djavan B, Milani S, Remzi M.
    Can J Urol; 2005 Feb 01; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [Abstract] [Full Text] [Related]

  • 3. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
    Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M.
    J Urol; 2001 Nov 01; 166(5):1679-83. PubMed ID: 11586201
    [Abstract] [Full Text] [Related]

  • 4. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
    Djavan B, Fong YK, Ravery V, Remzi M, Horninger W, Susani M, Kreuzer S, Boccon-Gibod L, Bartsch G, Marberger M.
    Eur Urol; 2005 Jan 01; 47(1):38-44; discussion 44. PubMed ID: 15582247
    [Abstract] [Full Text] [Related]

  • 5. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M.
    J Urol; 2000 Apr 01; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.
    Stewart CS, Leibovich BC, Weaver AL, Lieber MM.
    J Urol; 2001 Jul 01; 166(1):86-91; discussion 91-2. PubMed ID: 11435830
    [Abstract] [Full Text] [Related]

  • 10. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N, Lane BR, Li J, Moussa AS, Soriano M, Jones JS.
    J Urol; 2008 Oct 01; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
    Lane BR, Zippe CD, Abouassaly R, Schoenfield L, Magi-Galluzzi C, Jones JS.
    J Urol; 2008 May 01; 179(5):1746-50; discussion 1750. PubMed ID: 18343412
    [Abstract] [Full Text] [Related]

  • 13. Importance of peripheral biopsies in maximising the detection of early prostate cancer in repeat 12-core biopsy protocols.
    Philip J, Hanchanale V, Foster CS, Javlé P.
    BJU Int; 2006 Sep 01; 98(3):559-62. PubMed ID: 16925754
    [Abstract] [Full Text] [Related]

  • 14. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
    Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ.
    Urology; 2006 Feb 01; 67(2):343-8. PubMed ID: 16442594
    [Abstract] [Full Text] [Related]

  • 15. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
    Noguchi M, Stamey TA, Neal JE, Yemoto CE.
    J Urol; 2000 Jun 01; 163(6):1751-5. PubMed ID: 10799175
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
    Zlotta AR, Remzi M, Snow PB, Schulman CC, Marberger M, Djavan B.
    J Urol; 2003 May 01; 169(5):1724-8. PubMed ID: 12686818
    [Abstract] [Full Text] [Related]

  • 19. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R, Martínez-Jabaloyas JM, Soriano-Sarriá P, Ramos-Soler D, Pastor-Hernández F, Gil-Salom M.
    Urol Int; 2007 May 01; 78(4):328-33. PubMed ID: 17495491
    [Abstract] [Full Text] [Related]

  • 20. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR, McNeal JE, Gill H, Presti JC.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):386-91. PubMed ID: 15145152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.